Clinical trial · no report yet · Phase 1/Phase 2
NCT05608252
VS-6766+Abema+Fulv in Met HR+/HER- BC
- NCT05608252 ↗
- Recruiting
- Adrienne G. Waks
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 2 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Single Arm Phase 1/2 Trial of Abemaciclib + Avutometinib (VS-6766) + Fulvestrant in Metastatic HR+/HER2- Breast Cancer
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Breast Cancer; Hormone Receptor-positive Breast Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer
- Interventions
- VS-6766; Abemaciclib; Fulvestrant
- Arms
- Phase 1 Dose Escalation · Experimental
- Phase 2 Dose Expansion · Experimental
- Enrollment
- 63 (estimated)
- Primary outcomes
- Phase 1 Maximum tolerated dose (MTD)
- Phase 1 Recommended Phase II Dose (RP2D)
- Phase 2 Clinical benefit rate (CBR)
- Sponsor
- Adrienne G. Waks with Verastem, Inc., Eli Lilly and Company
- Start
- Feb 23, 2023
- Primary completion
- Dec 31, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05608252 · updated Apr 30, 2026